News Apitope announces IPO to fund MS drug development Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News Merck KGaA to develop immunotherapies with F-star German Merck has option to licence LAG3-PDL1 drug.
News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
